Internal Medicine, Pulmonary Disease · Clearwater, FL
NPI
1043291982
Since 2005
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
430 Morton Plant St, Suite 405
Clearwater, FL, 33756
Phone (727) 443-0611
Groups this clinician bills Medicare through
Medicare paid, 2024
$174K
2,116 services
Medicare patients, 2024
719
Average age 77
Drug cost, 2024
$1.0M
1,794 prescriptions
Company payments, 2025
$1,005
From 15 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Daniel A Orlando III was code 99233 (hospital e&m - subsequent), 340 times for 159 patients. In total Daniel A Orlando III billed 2,116 services in 35 codes, and Medicare paid $174K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-05-19.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99233 Hospital E&M - Subsequent | Facility | 340 | 159 | $92.14 | $31K |
| 99214 Office E&M - Established | Office | 294 | 200 | $91.76 | $27K |
| 99291 Critical Care E&M | Facility | 201 | 125 | $166.15 | $33K |
| 99232 Hospital E&M - Subsequent | Facility | 189 | 101 | $61.32 | $12K |
| 99215 Office E&M - Established | Office | 154 | 103 | $134.36 | $21K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 141 | 130 | $12.81 | $1,806 |
| 99223 Hospital E&M - Initial | Facility | 95 | 90 | $133.52 | $13K |
| 94729 Pulmonary Function Testing | Office | 89 | 86 | $41.31 | $3,677 |
| 94726 Pulmonary Function Testing | Office | 85 | 82 | $41.46 | $3,524 |
| 99213 Office E&M - Established | Office | 74 | 64 | $60.40 | $4,470 |
| 94060 Pulmonary Function Testing | Office | 49 | 49 | $28.81 | $1,412 |
| 99239 Hospital Discharge Management | Facility | 45 | 42 | $87.60 | $3,942 |
| 94010 Pulmonary Function Testing | Office | 39 | 37 | $20.42 | $796 |
| G0399 Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | Office | 37 | 37 | $71.42 | $2,643 |
| 94729 Pulmonary Function Testing | Facility | 29 | 29 | $6.73 | $195 |
By year: 2022 $191K for 2,108 services; 2023 $203K for 2,216 services; 2024 $174K for 2,116 services.
Medicare prescription drug claims, 2024
In 2024, the drug Daniel A Orlando III prescribed most often to Medicare patients was Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter), with 290 prescriptions and refills. In total Daniel A Orlando III wrote 1,794 Medicare prescriptions that cost $1.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 290 | 391 | 58 | $244K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 269 | 373 | 96 | $7,279 |
| Montelukast Sodium Generic | 140 | 358 | 38 | $1,893 |
| Breo Ellipta Fluticasone/Vilanterol | 129 | 151 | 20 | $57K |
| Prednisone Generic | 107 | 115 | 46 | $418 |
| Ventolin Hfa Albuterol Sulfate | 66 | 72 | 16 | $3,977 |
| Symbicort Budesonide/Formoterol Fumarate | 43 | 79 | Under 11 | $16K |
| Ipratropium Bromide Generic | 36 | 63 | 12 | $961 |
| Breyna Budesonide/Formoterol Fumarate | 31 | 39 | Under 11 | $8,337 |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | 31 | 31 | 16 | $131 |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 26 | 28 | Under 11 | $17K |
| Spiriva Respimat Tiotropium Bromide | 25 | 40 | Under 11 | $20K |
| Wixela Inhub Fluticasone Propion/Salmeterol | 25 | 35 | Under 11 | $1,981 |
| Modafinil Generic | 24 | 24 | Under 11 | $1,453 |
| Pantoprazole Sodium Generic | 20 | 36 | Under 11 | $270 |
Brand drugs: 974 claims; generic drugs: 820 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Daniel A Orlando III $1,005 ($1,005 in general payments such as food, travel and fees) from 15 companies. The largest payer was GlaxoSmithKline, LLC. with $212.
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. GSK | 11 | $212 |
| AstraZeneca Pharmaceuticals LP AZN | 7 | $151 |
| Abbvie Inc. ABBV | 4 | $106 |
| United Therapeutics Corporation UTHR | 3 | $91.46 |
| Jazz Pharmaceuticals Inc. JAZZ | 3 | $83.08 |
| Harmony Biosciences LLC HRMY | 4 | $72.99 |
| Insmed, Inc. INSM | 3 | $58.49 |
| Merck Sharp & Dohme LLC MRK | 2 | $57.41 |
| Amgen Inc. AMGN | 2 | $37.34 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $32.32 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.